At Taligen, we are committed to building and attracting a world-class team.
Collectively, our team’s employees, founders, and collaborators combine unparalleled expertise in the biology of the complement system and its role in human disease as well as in the discovery, development, and commercialization of novel protein therapeutics.
Abbie Celniker, Ph.D., Chief Executive Officer: Dr. Celniker has more than 20 years of experience in building biologics-focused businesses. Prior to joining Taligen, Dr. Celniker was Global Head of Biologics at Novartis. In this role, she built and managed the basic infrastructure and strategy for the late-stage discovery and development of protein therapeutics at Novartis. Previously, she held senior research and development position leadership roles with Millennium Pharmaceuticals, Wyeth BioPharma (Genetics Institute) and Genentech. Dr. Celniker holds a Ph.D. in molecular biology from the University of Arizona and a B.A. in biology from the University of California, San Diego.
Michael Holers, M.D., Chief Scientific Officer and Co-founder: Dr. Holers is one of the world’s leading experts in complement biology and has published more than 200 articles in the area. His research has focused on the role of complement in initiating inflammation and on the development of novel approaches to controlling complement activation in vivo. Dr. Holers has recently been the Scoville Professor and Head of the Division of Rheumatology at the University of Colorado Denver School of Medicine. He has served as a founding member of the International Complement Society and as chair of the Committee on Research, chair of the Scientific Advisory Committee and as a member of the Boards of Directors of the American College of Rheumatology and its Research and Education Foundation. Dr. Holers received his M.D. and completed post-doctoral training at Washington University School of Medicine in St. Louis, where he was an associate professor with tenure before he joined the faculty at the University of Colorado. He earned a B.S. in Biology from Purdue University.
Jeffrey Walsh, Chief Business Officer: Mr. Walsh has worked in the life sciences industry for over 20 years, holding executive level business management positions in several private and public pharmaceutical, diagnostic and biotechnology companies. His experience includes strategic partnerships, mergers & acquisitions transactions and private equity financings worth over $1.5 billion. Mr. Walsh led the development and growth of business development, strategic planning, business operations and financial management functions for both large pharma as well as mid size and start up biotech companies including leadership positions at SmithKline Beecham (now GlaxoSmithKline), PathoGenesis Corporation (now Chiron/Novartis Corporation), EXACT Sciences Corporation and Inotek Pharmaceuticals. Mr. Walsh holds a BA from Yale University and an MBA from Northwestern University’s Kellogg Graduate School of Management.
Sven Ante (Bill) Lundberg, MD, Chief Medical Officer: Dr. Lundberg joined Taligen Therapeutics as Chief Medical Officer in April 2010. Prior to joining Taligen, Dr. Lundberg held senior clinical and medical affairs roles in both large pharmaceutical and emerging biopharmaceutical companies, including Genzyme, Wyeth, Xanthus Pharmaceuticals and most recently, Antisoma Research Ltd after the acquisition of Xanthus in 2008. Dr. Lundberg brings a wealth of knowledge and experience in the fields of immunology and oncology. He received clinical training in internal medicine and oncology at Brigham and Women’s Hospital and Dana-Farber Cancer Institute, both at Harvard Medical School, and has held Research and Clinical Fellowship positions in Immunology and Oncology at the Dana-Farber Cancer Institute (Harvard Medical School) and the Whitehead Institute (MIT). Dr. Lundberg holds a B.S. degree in biology from the Massachusetts Institute of Technology and an MD from Stanford Medical School.
Christopher Horvath, D.V.M., Vice President of Preclinical Sciences: Dr. Horvath has worked in the biopharmaceutical industry for 17 years and has designed, conducted and submitted more than 250 nonclinical studies of cytokines, monoclonal antibodies, immunoconjugates, DNA vaccines, gene therapy agents and aptamers. Prior to Taligen, Dr. Horvath worked at Archemix Corp., Millennium Pharmaceuticals and LeukoSite, where he was responsible for the nonclinical development of aptamers for cardiovascular and inflammatory diseases, monoclonal antibodies for inflammatory and autoimmune diseases and immunoconjugates for cancer. Dr. Horvath received his DVM from Ohio State University and completed an internship in medicine at the University of Minnesota and a residency in surgery and M.S. in Clinical Nutrition from Michigan State University. He completed a postdoctoral fellowship in Respiratory Physiology at Albany Medical College and a fellowship in Comparative Pathology at Harvard Medical School’s New England Regional Primate Research Center (focused on immunopathology, macrophage function and immune disregulation).
Jill Porter, Ph.D., Vice President Biopharmaceutical Development: Dr. Porter has over 20 years of biopharmaceutical engineering, process development and manufacturing experience in both large pharmaceutical as well as emerging biotechnology firms. Dr. Porter most recently served as Vice President, Process Development and Engineering at Altus Pharmaceuticals. Prior to Altus, she was employed at Roche for 16 years in positions of increasing responsibility including Director of Biopharmaceuticals from February, 2000 through August, 2007. Dr. Porter holds an MBA from Columbia University, a Ph.D. in Agricultural Engineering from Purdue University and a B.S. in Chemical Engineering from the Massachusetts Institute of Technology.
Karen Tubridy, PharmD, Vice President, Clinical Operations and Regulatory Affairs: Dr. Tubridy joined Taligen as Vice President, Clinical Operations and Regulatory Affairs in April 2010. Prior to joining Taligen, Dr. Tubridy held clinical operations leadership and management roles within the biopharmaceutical industry for over twenty years with a particular emphasis in the areas of hematology, immunology and oncology. Prior to joining Taligen, Dr. Tubridy served as Senior Director of Clinical Operations for Biogen Idec’s Hemophilia franchise and Vice President of Clinical Operations at Syntonix Pharmaceuticals. Prior to Syntonix, Dr. Tubridy held management positions in program development at AVANT Immunotherapeutics and global medical affairs at Wyeth/Genetics Institute. Dr. Tubridy received her B.S. and PharmD degrees in Pharmacy from the Massachusetts College of Pharmacy and Allied Health Sciences, Boston, MA.